Human osteoclast formation and activity in vitro: Effects of alendronate

被引:85
作者
Breuil, V
Cosman, F
Stein, L
Horbert, W
Nieves, J
Shen, V
Lindsay, R
Dempster, DW
机构
[1] New York State Dept Hlth, Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY 10993 USA
[2] New York State Dept Hlth, Helen Hayes Hosp, Clin Res Ctr, W Haverstraw, NY USA
[3] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA
[4] Columbia Univ Coll Phys & Surg, Dept Epidemiol, New York, NY 10032 USA
[5] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA
关键词
D O I
10.1359/jbmr.1998.13.11.1721
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent advances in technique have made it possible to study human osteoclast (OC) formation and activity in vitro. The object of the present study was to determine the effects of alendronate (ALN) on human OCs generated from precursors obtained from standard peripheral blood samples. Peripheral blood mononuclear cells from 14 postmenopausal women were cocultured with Sn stromal cells on bone slices in the presence of 10(-7) M 1,25-dihydroxyvitamin D-3, 10(-8) M dexamethasone, and 25 ng/ml human macrophage colony-stimulating factor. After 21 days, the cultures contained numerous OCs, which were characterized by multinuclearity, the presence of tartrate-resistant acid phosphatase, calcitonin and vitronectin receptors, and the ability to resorb substantial amounts of bone, which was inhibited by calcitonin, The percentage area of bone resorbed per slice was highly correlated (r = 0.89, p < 0.001) with the concentration of Type I collagen cross-linked C-telopeptides (CTx) released into the culture medium. When added to the medium, ALN inhibited bone resorption at concentrations less than or equal to 10(-7) M, At 10(-7) M, inhibition was achieved primarily by a reduction in OC activity without a marked effect on OC number. At the highest concentration studied (10(-5) M), both OC number and resorption were profoundly decreased. Overnight preincubation of bone slices in ALN, without further exposure to ALN, resulted in an inhibition of resorption that was similar to that seen when ALN was present in the medium throughout the entire culture period. We conclude that, except at very high concentrations, the predominant mechanism of action of AW is to inhibit the activity of differentiated human OCs with little or no effect on recruitment. Interaction between the OC and ALN on the bone surface is an important component of the inhibitory mechanism. Measurement of CTx in tissue culture medium is a convenient method for assessment of bone resorption in human OC cultures and offers a number of advantages over morphometric analysis of the bone slice.
引用
收藏
页码:1721 / 1729
页数:9
相关论文
共 40 条
[1]   Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone [J].
Apone, S ;
Lee, MY ;
Eyre, DR .
BONE, 1997, 21 (02) :129-136
[2]   A COMPARATIVE-STUDY OF DISAGGREGATED CHICK AND RAT OSTEOCLASTS INVITRO - EFFECTS OF CALCITONIN AND PROSTAGLANDINS [J].
ARNETT, TR ;
DEMPSTER, DW .
ENDOCRINOLOGY, 1987, 120 (02) :602-608
[3]  
Azria Moise, 1996, P1083
[4]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[5]   THE OSTEOCLAST FUNCTIONAL ANTIGEN, IMPLICATED IN THE REGULATION OF BONE-RESORPTION, IS BIOCHEMICALLY RELATED TO THE VITRONECTIN RECEPTOR [J].
DAVIES, J ;
WARWICK, J ;
TOTTY, N ;
PHILP, R ;
HELFRICH, M ;
HORTON, M .
JOURNAL OF CELL BIOLOGY, 1989, 109 (04) :1817-1826
[6]  
DEMPSTER DW, 1987, J BONE MINER RES, V2, P443
[7]  
DEMPSTER DW, 1990, J BONE MINER RES S2, V5, pS95
[8]   Treatment with alendronate prevents fractures in women at highest risk - Results from the fracture intervention trial [J].
Ensrud, KE ;
Black, DM ;
Palermo, L ;
Bauer, DC ;
BarrettConnor, E ;
Quandt, SA ;
Thompson, DE ;
Karpf, DB .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (22) :2617-2624
[9]  
FLANAGAN AM, 1992, INT J EXP PATHOL, V73, P387
[10]  
FLANAGAN AM, 1988, CANCER, V62, P1139, DOI 10.1002/1097-0142(19880915)62:6<1139::AID-CNCR2820620617>3.0.CO